EGFR and non-small cell lung carcinoma: For example, EGFR activating mutations as in frame deletions in exon 19 or the Leu858Arg (L858R) point mutation in exon 21 are related with the therapeutic effect of first generation quinazoline reversible EGFR tyrosine kinase inhibitors (TKIs) in NSCLC patients.